What's in Dermax SA's pipeline?

Dermax SA has 2 drugs in our index: 0 marketed, 0 filed, 2 in Phase 3, 0 in Phase 2, 0 in Phase 1.

Which companies overlap with Dermax SA's portfolio?

No competitive overlap detected.

Subscribe to /feed/company/dermax-sa.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-15 · How we verify

Dermax SA pipeline: 0 marketed, 0 filed, 2 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 2 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Drug	Generic	Phase	Class	Target	Area	First approval
Podofilox Gel 0.5%	Podofilox Gel 0.5%	phase 3	Antimitotic agent	Tubulin	Oncology
Condylox Topical Gel 0.5%	Condylox Topical Gel 0.5%	phase 3	Antimitotic agent	Tubulin	Dermatology

No regulatory actions in the last 90 days for this portfolio.

No PDUFA dates in the next 180 days for this portfolio.

No upcoming patent expiries for this portfolio.

No competitive overlap data.

Every new pipeline event for Dermax SA:

Drug Landscape (2026). Dermax SA — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/dermax-sa. Accessed 2026-05-15.